Navigation Links
First Patient of NOTES Investigational Device Exemption (IDE) Study Successfully Treated With Ethicon Endo-Surgery Devices
Date:7/9/2009

CINCINNATI, July 9 /PRNewswire/ -- Ethicon Endo-Surgery, Inc. today announced the successful treatment of the first patient of its IDE feasibility trial. The case, which was performed at The Ohio State University Center for Minimally Invasive Surgery, marks the first natural orifice translumenal endoscopic surgery (NOTES) procedure involving the company's investigational devices. NOTES is a surgical method in which external incisions are eliminated, potentially leading to reduced pain, a quicker recovery and a faster return to normal activities for the patient.

The Ethicon Endo-Surgery Toolbox* for natural orifice surgery is a novel, comprehensive suite of devices specifically designed for this new approach to surgery. Several of these devices are featured in studies accepted for presentation this week at the 4th International NOSCAR Conference on NOTES in Boston. The patient treated at The Ohio State University Medical Center underwent a transgastric diagnostic peritoneoscopy with laparoscopic assistance prior to a laparoscopic gastric bypass procedure. The transgastric diagnostic peritoneoscopy is an exploratory surgery of the abdomen with the potential to treat adhesions, biopsy, etc.

"Using the Ethicon Endo-Surgery Toolbox, we were able to perform a thorough diagnostic peritoneoscopy in about the same timeframe as a typical laparoscopic procedure using the patient's mouth as the primary external access point. This protocol was designed to collect device data as well as intra-operative procedure data on the Ethicon Endo-Surgery Toolbox to assess the feasibility of using these devices within this procedural application," said Jeffrey Hazey, MD, FACS, assistant professor at the Ohio State University Center for Minimally Invasive Surgery. "I believe this study will serve as a critical step in advancing NOTES and NOTES specific technology, which holds great promise for improving surge
'/>"/>

SOURCE Ethicon Endo-Surgery, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...wire-FirstCall/--NuVasive,Inc.(Nasdaq: NUVA ),amed...imallydisruptivesurgicaltreatmentsforthespine,anno...vember30,2009,at5:30p.m.ET/2:30p.m.PT.Theconferenc...ntfortheCompany,sproductsandwillincludecommentsfro...n.Thedial-innumbersare1-877-407-4018fordomesticcal...
(Date:11/25/2009)...dJOHANNESBURG,November25/PRNewswire/--,iThembaPhar...cedtoday,thattheyhavesignedacollaborativeagreement...is,sworldclasscomputationalchemistryandleaddiscove...iontoprovidemedicinaland,syntheticchemistrysupport...entnetwork.iThembaPharmaceuticalsandPyxisDiscovery...
(Date:11/24/2009)...wswire/-- ,, WHAT:RomHoubens,aBelgianmanthought...wasactuallyfullyconsciousandawakeduringthattimeand...oxEyeMaxwasfeaturedinthesegmenttoillustratehowpeop...communication. ,, WHEN:GoodMorningAmerica-- Tue...ch.com ,, WHO:RomHoubenswasanengineeringstu...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2FDA Approves NovoLog 28R 29 Labeling Update 51814 1FDA Approves NovoLog 28R 29 Labeling Update 51814 2FDA Approves NovoLog 28R 29 Labeling Update 51814 3FDA Approves NovoLog 28R 29 Labeling Update 51814 4U S Students Academic Interests Tend to Wane in Middle School 51812 1U S Students Academic Interests Tend to Wane in Middle School 51812 2Michael Steele Chairman of the Republican National Committee Will Hold a Press Conference on Health Care the Republican Alternative at 9 am on Mon 51810 1
...at data,presented recently at the 17th Annual Meet...iology demonstrate that the Genous Bio-engineered ...eluting stents., Presented by Federico Piscione, ...fessor with the Federico II University of Naples,s...dicine and Cardiovascular,Sciences, the data were ...
...ion Application currently u...erapeutics, Inc. (CTI),(Nasdaq: CTIC ; MTA) today...domized phase III trial comparing OPAXIO(TM) (pacl...orelbine for the treatment of PS 2,(performance st...ll cell,lung cancer (NSCLC) in the Journal of Thor...
Other Medicine Technology:Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 2Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5
(Date:11/27/2009)...UILLY-SUR-SEINE,France,Nov.27/PRNewswire/--TeamGar...teamdedicatedtoethicalsportinganddevelopingthenext...illbecomeTeamGarmin-TransitionswiththeadditionofTr...Opticalistheworld,sleadingmanufacturerofadaptiveey...yinthewidestselectionofspectaclelensessuchasTransi...
(Date:11/27/2009)... XenaCare Holdings has announced th...is Foundation, one of the largest nonprofit organi... health education. , Delr... Holdings, Inc. (OTCBB: XCHO), a company specializ...nsumer healthcare products, has announced today th...
(Date:11/27/2009)...tes to bring unprecedented medical, economic burde...HealthDay News) -- The number of people with diabe...r the next 25 years, a new study predicts. , Th...lion people with the disease, up from 23.7 million...ng people with diabetes will triple, the study als...
(Date:11/27/2009)... Voyant Health™ announced tod...as licensed its TraumaCad Enterprise orthopedic te...w solution. , (PRWEB) Nov...oday that Spectrum Health (Grand Rapids, Michigan)...templating solution and its TraumaCad Extend workf...
(Date:11/27/2009)... Specialist manufacturers who use m...re saving millions of dollars by bringing in techn... Increasing numbers of pro-active medical manufact...the concept stage of their projects, ensuring that...gn processes or potentially outdated technology. ...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4
...nsula Medical School in the South West of England ...eel that doctors providing out of hours services i... Researchers held group discussions and carried ou...ngland. , Under the GP contract, which came into ...
... 29 CalbaTech, Inc.,(OTC Bulletin Board: CLBE), a...aTech.com ) concentrating on the collection and ba...apeutic uses and providing,products and platforms ...th has renewed LifeStem,s biologics license.,LifeS...
...Role as Governments and Civil Society in the ...Crisis, NEW DELHI, India, BEIJING and BANGKOK, Th...IDS Day 2007, hundreds, perhaps thousands, of men,...but ever-growing crisis that many governments in t...
...the hip is a growing problem that will continue to... have reported on risk factors for developing OA, ...ct its prognosis. A new study published in the Dec...r disease progression and to find out how many und...
...it has obtained agreement with the United States, ...n of its pivotal study, protocol for SP1049C for t... upper gastrointestinal tract, ...rsus BSC alone for the treatment of patients with ...
...) -- There are estimated to be between 50,000 --...ronic Immune Thrombocytopenic Purpura (ITP), an au...ber of platelets in their blood -- causing bruises...rk-Presbyterian Hospital/Weill Cornell Medical Cen...
Other Medicine News:Health News:Out of hours doctors reluctant to do home visits, say patients 2Health News:CalbaTech Reports That LifeStem's Biologics License Has Been Renewed 2Health News:CalbaTech Reports That LifeStem's Biologics License Has Been Renewed 3Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 2Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 3Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 4Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 5Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 6Health News:Identifying patients at high risk for total hip replacement 2Health News:Supratek Pharma Inc. announced today that under the Special Protocol 2Health News:Eltrombopag studied in Idiopathic Thrombocytopenic Purpura 2
...ested Timeter® Classic Flowmeters demonstrates...oviders and patients alike. You can see it in the ... can see it in the performance, year after year. E...d and engineered to the highest standards of perfo...
Soft-Touch Timeter® 15 LPM Dual Oxygen Flowmeter w/Y Bar & 2 Power Take Off
Soft-Touch Timeter® 15 LPM Dual Oxygen Flowmeter w/T Bar
Soft-Touch Timeter® 8 LPM Flowmeter
Medicine Products: